PFA and LTA measurements in patients with blood group O vs non-O
| . | Blood group O (n = 188) . | Blood group non-O (n = 211) . | P . | BHC . | P* . | BHC* . | |
|---|---|---|---|---|---|---|---|
| PFA-100 | |||||||
| PFA-100 epinephrine, median (IQR), s | 135.5 (122.0-164.5) | 131 (110.0-147.0) | 0.003 | <.05 | .164 | NS | |
| PFA-100 adenosine diphosphate, mean (SD), s | 107.2 (34.5) | 88.1 (89.7) | 0.018 | <.05 | .891 | NS | |
| LTA | |||||||
| ADP, median (IQR), % | 94.0 (82.0-104.0) | 93.0 (80.0-104.0) | 0.425 | NS | .296 | NS | |
| Arachidonic acid, median (IQR), % | 89.0 (83.0-96.0) | 89.0 (82.0-97.0) | 0.831 | NS | .788 | NS | |
| Collagen, mean (SD), % | 91.5 (12.7) | 93.2 (12.9) | 0.184 | NS | .310 | NS | |
| Epinephrine, median (IQR), % | 95.0 (85.0-103.0) | 95.0 (86.5-103.0) | 0.783 | NS | .795 | NS | |
| Ristocetin (1.2 mg/mL), median (IQR), % | 94.0 (88.0-99.0) | 94.0 (87.0-101.0) | 0.786 | NS | .644 | NS | |
| . | Blood group O (n = 188) . | Blood group non-O (n = 211) . | P . | BHC . | P* . | BHC* . | |
|---|---|---|---|---|---|---|---|
| PFA-100 | |||||||
| PFA-100 epinephrine, median (IQR), s | 135.5 (122.0-164.5) | 131 (110.0-147.0) | 0.003 | <.05 | .164 | NS | |
| PFA-100 adenosine diphosphate, mean (SD), s | 107.2 (34.5) | 88.1 (89.7) | 0.018 | <.05 | .891 | NS | |
| LTA | |||||||
| ADP, median (IQR), % | 94.0 (82.0-104.0) | 93.0 (80.0-104.0) | 0.425 | NS | .296 | NS | |
| Arachidonic acid, median (IQR), % | 89.0 (83.0-96.0) | 89.0 (82.0-97.0) | 0.831 | NS | .788 | NS | |
| Collagen, mean (SD), % | 91.5 (12.7) | 93.2 (12.9) | 0.184 | NS | .310 | NS | |
| Epinephrine, median (IQR), % | 95.0 (85.0-103.0) | 95.0 (86.5-103.0) | 0.783 | NS | .795 | NS | |
| Ristocetin (1.2 mg/mL), median (IQR), % | 94.0 (88.0-99.0) | 94.0 (87.0-101.0) | 0.786 | NS | .644 | NS | |
ADP, adenosine diphosphate.
ANCOVA, adjusted for sex and VWF:Ag, VWF:RCo, and FVIII levels.